At a glance
ClinicalIndex Comparison Record- ✓Diagnosed with sepsis, evaluated by infectious disease physician, and candidate for piperacillin/tazobactam, imipenem, or meropenem as empiric treatment
- ✕History of allergy to any of the proposed antibiotics (piperacillin/tazobactam, imipenem, or meropenem)
- ✕Chronic kidney disease or acute renal failure
- ✕Acute liver failure of any cause
- ✕In palliative or supportive care only
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of the Administration of Betalactam Antibiotics in Continuous or Extended Infusion Compared to Intermittent Infusion in Patients With Sepsis in Two Pediatric Third-level Care Hospitals
In Brief
A clinical study evaluating Intermittent Piperacillin/tazobactam, Continuous Piperacillin/tazobactam, and 4 other interventions for Sepsis. Completed, enrolled 426 participants across 2 sites.
Detailed Summary
This study evaluates the efficacy and safety of the administration of betalactam antibiotics in prolonged infusion compared to intermittent infusion in children with sepsis. Half of participants will receive piperacillin/tazobactam, imipenem or meropenem in continuous or extended infusion, while the other half will receive piperacillin/tazobactam, imipenem or meropenem in intermittent infusion.
Study Details
Timeline
Interventions
Piperacillin/tazobactam administered in 30 minutes infusion.
Piperacillin/tazobactam administered in 24 hours infusion.
Imipenem administered in 60 minutes infusion.
Imipenem administered in 6 hours infusion.
Meropenem administered in 60 minutes infusion.
Meropenem administered in 8 hours infusion.